Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 277

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

Open access
Peterson, Leigh, Taylor, Doug, Roddy, Ronald, Belai, Ghiorghis, Phillips, Pamela, Nanda, Kavita, Grant, Robert, Clarke, Edith Essie Kekawo, Doh, Anderson Sama, Ridzon, Renee, Jaffe, Howard S, Cates, Willard·2007·PLoS Clinical Trials
DOI 10.1371/journal.pctr.0020027
Open this paper in CoChat — free account

Abstract

OBJECTIVES: The objective of this trial was to investigate the safety and preliminary effectiveness of a daily dose of 300 mg of tenofovir disoproxil fumarate (TDF) versus placebo in preventing HIV infection in women. DESIGN: This was a phase 2, randomized, double-blind, placebo-controlled trial. SETTING: The study was conducted between June 2004 and March 2006 in Tema, Ghana; Douala, Cameroon; and Ibadan, Nigeria. PARTICIPANTS: We enrolled 936 HIV-negative women at high risk of HIV infection into this study. INTERVENTION: Participants were randomized 1:1 to once daily use of 300 mg of TDF or placebo. OUTCOME MEASURES: The primary safety endpoints were grade 2 or higher serum creatinine elevations (>2.0 mg/dl) for renal function, grade 3 or 4 aspartate aminotransferase or alanine aminotransferase elevations (>170 U/l) for hepatic function, and grade 3 or 4 phosphorus abnormalities (<1.5 mg/dl). The effectiveness endpoint was infection with HIV-1 or HIV-2. RESULTS: Study participants contributed 428 person-years of laboratory testing to the primary safety analysis. No significant differences emerged between treatment groups in clinical or laboratory safety outcomes. Study participants contributed 476 person-years of HIV testing to the primary effectiveness analysis, during which time eight seroconversions occurred. Two were diagnosed in participants randomized to TDF (0.86 per 100 person-years) and six in participants receiving placebo (2.48 per 100 person-years), yielding a rate ratio of 0.35 (95% confidence interval = 0.03-1.93), which did not achieve statistical significance. Owing to premature closures of the Cameroon and Nigeria study sites, the planned person-years of follow-up and study power could not be achieved. CONCLUSION: Daily oral use of TDF in HIV-uninfected women was not associated with increased clinical or laboratory adverse events. Effectiveness could not be conclusively evaluated because of the small number of HIV infections observed during the study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pctr.0020027

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 277

Metadata

Authors
Peterson, L., Taylor, D., Roddy, R., Belai, G., Phillips, P., Nanda, K., Grant, R., Clarke, E. E. K., Doh, A. S., Ridzon, R., Jaffe, H. S., & Cates, W.
Venue
PLoS Clinical Trials
Publisher
Public Library of Science (PLoS)
Published
2007-05-25
Volume
2
Issue
5
Pages
e27
ISSN
1555-5887 (ISSN-L)
DOI
10.1371/journal.pctr.0020027
OpenAlex
W2038662816
Cited by
277
References
21
FWCI
16.85
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1371/journal.pctr.0020027
The paper
Peterson, L., Taylor, D., Roddy, R., Belai, G., Phillips, P., Nanda, K., Grant, R., Clarke, E. E. K., Doh, A. S., Ridzon, R., Jaffe, H. S., & Cates, W. (2007). Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. PLoS Clinical Trials. https://doi.org/10.1371/journal.pctr.0020027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.